Last updated: April 23, 2026
EP1224170 (European Patent Office) Drug Patent: Scope, Claims, and European Landscape
What does EP1224170 protect?
EP1224170 is an EPO-published patent in the drug space. It contains product and/or use rights typical for European pharmaceutical filings and has an enforceable scope that is driven by three claim elements: (1) the drug entity defined by chemical/structural parameters, (2) the method of preparation or formulation parameters (if present), and (3) the claimed therapeutic use (indication) and patient/dosage characteristics (if present).
However, a complete, accurate claim-by-claim scope and landscape requires the exact claim text (independent and dependent claims) and the published claim set for the relevant status (A1/A2, granted B1/B2, and amended versions post-opposition if any). The question asks for “detailed analysis of the scope and claims,” and “patent landscape,” which cannot be produced correctly without the authoritative claim text and bibliographic dossier.
What is the claimed subject matter (independent claim scope)?
EP drug patents at this publication stage typically use one or more independent claims that define:
- A compound (or salt/polymorph/formulation) by structure and/or Markush language
- A pharmaceutical composition comprising the compound plus one or more excipients
- A therapeutic method for a named disease or clinical endpoint
For EP1224170, the precise boundaries (what is included and excluded) depend on:
- The exact chemical definition in the independent compound claim (generic scaffold vs. fully specified structures; salt and hydrate coverage; stereochemistry)
- Whether the independent claim includes “consisting of” vs. “comprising” language
- The route of administration and dosage regimen limits
- The indication language and any patient stratification or biomarker restriction
Without the published claim text, any attempt to reconstruct the scope risks factual error, which is not acceptable for a patent-landscape assessment.
How broad are the likely claim terms in EP1224170?
At EPO, breadth is driven by claim drafting choices:
- Compound breadth
- Markush groups expand coverage by allowing alternatives within structural definitions.
- Explicit stereochemical naming narrows coverage to a defined configuration.
- Salt/form polymorph breadth
- “Pharmaceutically acceptable salts” can be broad (subject to support and enablement).
- Specified polymorphs and hydrates materially narrow the scope.
- Therapeutic use breadth
- “Treatment of” a broad disease phrase expands scope.
- Narrow endpoints and specific patient groups reduce it.
- Method-of-treatment breadth
- “Administering” without dosage limits often leaves more room for design-around.
- Fixed dose ranges and schedules constrain clinical implementation.
EP1224170’s exact breadth profile cannot be mapped accurately without the claim set.
European Patent Office claim set: what the analysis must anchor
A “scope and claims” analysis for EP1224170 must anchor on:
- Publication: EP1224170 (including A1/A2 content)
- Granted claim set (B1/B2 if granted)
- Opposition/amendment outcome (as EPO claim text changes during prosecution and after opposition)
- Claim dependencies (to understand what dependent claims add vs. what they limit)
None of these required textual inputs are present in the prompt.
Patent landscape around EP1224170 (Europe): what matters
A proper European patent landscape for a specific EPO publication typically maps:
- Family members (EP, priority, and corresponding jurisdictions)
- Related European patents by the same applicant (same compound class or same indication)
- Blocking patents (earlier priority filings covering same chemical matter or same use)
- Design-around space (unclaimed salts, stereoisomers, formulations, and indication carve-outs)
- Status signals
- Opposition events
- Lapse/withdrawal
- Grant and remaining term in the EPO system
A landscape also needs:
- The compound identity and drug class
- The indication(s)
- The priority dates and key filing dates
- The applicant/assignee and inventors
Without those, a landscape would be speculative.
What can be concluded from the prompt alone
The prompt identifies only:
- the document number: EP1224170
- the request scope: “drug patent EP1224170”
It does not provide:
- claim text
- applicant/inventor
- priority date
- grant status
- indication
- compound identity
Under these constraints, producing a detailed scope/claims and European landscape would require guessing, which would compromise accuracy.
Key Takeaways
- EP1224170 can be analyzed in full only from its authoritative published and/or granted claim text and procedural status.
- A correct European patent landscape must map family, blocking filings, and opposition outcomes using the patent’s identity (compound/use) and status.
- The prompt does not include the required dossier facts, so a complete, accurate analysis cannot be provided.
FAQs
1) Can a detailed claim-scope analysis be produced from EP1224170’s number alone?
No. Scope analysis requires the exact claim set and current claim status.
2) What drives the enforcement breadth of an EPO drug patent like EP1224170?
Independent claim definition (compound/form/use), plus whether dependent claims add or limit (salt/form, dosage, route, indication).
3) What does a European patent landscape need to include for investment or R&D decisions?
Family mapping, related filings around the same matter and use, opposition/grant status, and design-around gaps.
4) How does opposition affect EP claim scope?
EPO opposition can narrow claims through amendments and can delete unsupported breadth.
5) What is the minimum data needed to map claim boundaries and landscape correctly?
The patent’s authoritative claims (published and granted) plus bibliographic and procedural status.
References (APA)
[1] European Patent Office. EP1224170 (publication record).
